Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.50 |
| ▸ | RXRB | P28702 | 4/20 | 0.50 |
| ▸ | RXRG | P48443 | 4/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.48 |
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | RARG | P13631 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483769 | 0.82 | RARB (0.56) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL17117601 | 0.82 | RXRA (0.48) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL15158788 | 0.81 | RXRA (0.47) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL8683660 | 0.80 | RXRA (0.46) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL2093706 | 0.80 | PDK2 (0.38) | RXRARXRBRXRGPDK2CYP3A4 | |
| SCHEMBL3176733 | 0.79 | RXRA (0.54) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL2095622 | 0.78 | KDM1A (0.40) | RXRARXRBRXRGPDK2 | |
| SCHEMBL2195316 | 0.77 | RXRA (0.47) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL9507898 | 0.77 | PPARG (0.50) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL9551721 | 0.77 | CYP3A4 (0.53) | RXRARXRBRXRGCYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0339521-B1 | PROCESS FOR MANUFACTURING TETRALIN DERIVATIVES, AND TETRALIN DERIVATIVES | BASF Aktiengesellschaft (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-4950369-A | Preparation of tetralin derivatives, and novel tetralin derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1990-08-21 | — | — | US | disclosed |
| EP-0339521-A1 | Process for manufacturing tetralin derivatives, and tetralin derivatives | BASF Aktiengesellschaft (DE) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | RXRA 71/4885RXRB 67/4885RXRG 92/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | RXRA 179/4885RXRB 138/4885RXRG 289/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | RXRA 121/4885RXRB 92/4885RXRG 128/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | RXRA 126/4885RXRB 91/4885RXRG 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.